373 related articles for article (PubMed ID: 29861388)
1. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.
Iepsen EW; Zhang J; Thomsen HS; Hansen EL; Hollensted M; Madsbad S; Hansen T; Holst JJ; Holm JC; Torekov SS
Cell Metab; 2018 Jul; 28(1):23-32.e3. PubMed ID: 29861388
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.
Iepsen EW; Have CT; Veedfald S; Madsbad S; Holst JJ; Grarup N; Pedersen O; Brandslund I; Holm JC; Hansen T; Torekov SS
Cell Rep Med; 2020 Apr; 1(1):100006. PubMed ID: 33205056
[TBL] [Abstract][Full Text] [Related]
3. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
Clemmensen C; Finan B; Fischer K; Tom RZ; Legutko B; Sehrer L; Heine D; Grassl N; Meyer CW; Henderson B; Hofmann SM; Tschöp MH; Van der Ploeg LH; Müller TD
EMBO Mol Med; 2015 Mar; 7(3):288-98. PubMed ID: 25652173
[TBL] [Abstract][Full Text] [Related]
4. Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass.
Iepsen EW; Zhang J; Hollensted M; Madsbad S; Hansen T; Holst JJ; Jørgensen NR; Holm JC; Torekov SS
J Bone Miner Metab; 2020 Jan; 38(1):117-125. PubMed ID: 31471646
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
Kadouh H; Chedid V; Halawi H; Burton DD; Clark MM; Khemani D; Vella A; Acosta A; Camilleri M
J Clin Endocrinol Metab; 2020 May; 105(5):1552-63. PubMed ID: 31665455
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons.
Adams JM; Pei H; Sandoval DA; Seeley RJ; Chang RB; Liberles SD; Olson DP
Diabetes; 2018 Aug; 67(8):1538-1548. PubMed ID: 29776968
[TBL] [Abstract][Full Text] [Related]
7. Weight and Glycemic Control Outcomes of Bariatric Surgery and Pharmacotherapy in Patients With Melanocortin-4 Receptor Deficiency.
Fojas EGF; Radha SK; Ali T; Nadler EP; Lessan N
Front Endocrinol (Lausanne); 2021; 12():792354. PubMed ID: 35095762
[TBL] [Abstract][Full Text] [Related]
8. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
[TBL] [Abstract][Full Text] [Related]
9. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
[TBL] [Abstract][Full Text] [Related]
10. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
11. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
Silver HJ; Olson D; Mayfield D; Wright P; Nian H; Mashayekhi M; Koethe JR; Niswender KD; Luther JM; Brown NJ
Diabetes Obes Metab; 2023 Aug; 25(8):2340-2350. PubMed ID: 37188932
[TBL] [Abstract][Full Text] [Related]
12. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
Burcelin R; Gourdy P
Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
[TBL] [Abstract][Full Text] [Related]
13. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
Jensterle M; Pirš B; Goričar K; Dolžan V; Janež A
Eur J Clin Pharmacol; 2015 Jul; 71(7):817-24. PubMed ID: 25991051
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
Pastel E; McCulloch LJ; Ward R; Joshi S; Gooding KM; Shore AC; Kos K
Clin Sci (Lond); 2017 Mar; 131(5):343-353. PubMed ID: 28049736
[TBL] [Abstract][Full Text] [Related]
16. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.
Chedid V; Vijayvargiya P; Carlson P; Van Malderen K; Acosta A; Zinsmeister A; Camilleri M
Neurogastroenterol Motil; 2018 Jul; 30(7):e13313. PubMed ID: 29488276
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy.
Zaitoon H; Lubetzky R; Amir AZ; Moran-Lev H; Sagi L; Yacobi-Bach M; Borger O; Chorna E; Lebenthal Y; Brener A
Acta Diabetol; 2023 Aug; 60(8):1099-1108. PubMed ID: 37160786
[TBL] [Abstract][Full Text] [Related]
18. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.
Frikke-Schmidt H; Hultman K; Galaske JW; Jørgensen SB; Myers MG; Seeley RJ
Mol Metab; 2019 Mar; 21():13-21. PubMed ID: 30685336
[TBL] [Abstract][Full Text] [Related]
19. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
20. The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review.
Ng VWW; Gerard G; Koh JJK; Loke KY; Lee YS; Ng NBH
Clin Obes; 2024 Jun; 14(3):e12642. PubMed ID: 38273176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]